Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Classical hematology 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 1Anemia 1

Interventions

venetoclax 47Cyclophosphamide 43Specimen Handling 42Cytarabine 41fludarabine 32Biopsy 31Azacitidine 25Rituximab 20Methotrexate 17fludarabine phosphate 16blinatumomab 16Vincristine 15Daunorubicin 15Dexamethasone 14ibrutinib 13Whole-Body Irradiation 13Prednisone 13Magnetic Resonance Spectroscopy 13Injections 13obinutuzumab 11merphos 11Mercaptopurine 11Filgrastim 11Calcium Dobesilate 11asciminib 10X-Rays 10Stem Cell Transplantation 10Mycophenolic Acid 10Doxorubicin 10decitabine and cedazuridine drug combination 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pharmacogenomic Testing × Other hematologic neoplasm × 30 days × Clear all
NCT02048813 2026-05-29

Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

National Cancer Institute (NCI)

Phase 3 Active not recruiting
529 enrolled 12 charts 1 FDA
Classical hematologyLymphoidOther hematologic neoplasm

Anemia, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡